Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy-Reference-Cited by-同舟云学术

Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy

Published:2015-03 Issue:2 Volume:94 Page:109-129
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Schwebe Matthias,Ameling Sabine,Hammer Elke,Monzel Judith V.,Bonitz Karina,Budde Susanne,Schult Kathleen,Oswald Stefan,Scheuch Eberhard,Grube Markus,Poesch Axel,Budde Thomas,Ewert Ralf,Schroeder Henry W.S.,Kroemer Heyo K.,Bien-Möller Sandra

Funder

Actelion Pharmaceuticals Ltd. (Switzerland)

Encysive Pharmaceuticals Inc. (Houston, USA)

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference61 articles.

1. The anthracyclines: will we ever find a better doxorubicin?;Weiss;Semin Oncol,1992

2. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy;Press;J Clin Oncol,2011

3. DNA complexing antibiotics: daunomycin, adriamycin and their derivatives;Marco;Arzneimittelforschung,1975

4. Hydroxyl radical production and DNA damage induced by anthracycline-iron complex;Muindi;FEBS Lett,1984

5. Adriamycin-induced changes in the surface membrane of sarcoma 180 ascites cells;Murphree;Biochim Biophys Acta,1981

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endothelin Receptor Blocker Reverses Breast Cancer–Induced Cardiac Remodeling;JACC: CardioOncology;2023-10

2. Low-dose of polystyrene microplastics induce cardiotoxicity in mice and human-originated cardiac organoids;Environment International;2023-09

3. Emerging Roles of Phospholipase C Beta Isozymes as Potential Biomarkers in Cardiac Disorders;International Journal of Molecular Sciences;2023-08-23

4. Upregulation of Biomarker Limd1 Was Correlated with Immune Infiltration in Doxorubicin-Related Cardiotoxicity;Mediators of Inflammation;2023-03-23

5. Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction;Cardiovascular Research;2022-05-31